April 15 (Reuters) - Johnson & Johnson JNJ.N:
J&J EXEC SAYS EXPECTS APPROVAL OF CAPLYTA LATER THIS YEAR AS AN ADJUNCTIVE TREATMENT FOR MAJOR DEPRESSIVE DISORDER - CONF CALL
J&J EXEC SAYS IMPLEMENTING A RESTRUCTURING PROGRAM TO SIMPLIFY AND FOCUS THE OPERATIONS OF ITS SURGERY BUSINESS - CONF CALL
J&J EXEC SAYS PLAN TO EXIT CERTAIN NON STRATEGIC PRODUCT LINES GLOBALLY & OPTIMIZE SELECT SITES ACROSS THE NETWORK FOR SURGERY BUSINESS
J&J EXEC SAYS CO EXPECTS SOME MODEST SHORT TERM REVENUE DISRUPTION IN SURGERY BUSINESS OF ABOUT $250 MILLION OVER THE NEXT TWO YEARS
J&J EXEC SAYS RESTRUCTURING PROGRAM FOR SURGERY BUSINESS IS EXPECTED TO BE COMPLETED IN 2027 WITH COST ESTIMATED AT ABOUT $900 MILLION
J&J CEO SAYS "NOT TARIFFS, BUT TAX POLICY" IS THE MOST EFFECTIVE WAY TO BUILD MANUFACTURING CAPACITY IN THE US FOR MEDICAL DEVICES AND PHARMACEUTICALS
J&J CEO SAYS PHARMACEUTICALS "TARIFFS CAN CREATE DISRUPTIONS IN THE SUPPLY CHAIN, LEADING TO SHORTAGES"
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。